PeerVoice Oncology & Haematology Audio

By PeerVoice

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  1. 1.
    An Immune System in Double Trouble: What Is ‘Best Practice’ for Managing Patients With Lymphoproliferative Malignancies?
    41:28
  2. 2.
    Therapeutic Sequencing in Patients With Advanced or High Risk Hodgkin Lymphoma: Strategies in Action
    20:47
  3. 3.
    Improving Outcomes in Non-Metastatic CRPC: Case by Case
    20:05
  4. 4.
    What's on the Radio? 2021 Data Broadcast on Radioligands in Men With CRPC
    18:47
  5. 5.
    Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses
    8:52
  6. 6.
    Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?
    58:25
  7. 7.
    Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?
    26:47
  8. 8.
    Radioligand Therapy in mCRPC: A Team Effort
    28:59
  1. 9.
    Advanced Basal Cell Carcinoma: An Exploration of Clinical Challenges and What the Future Could Hold
    58:49
  2. 10.
    "Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do"
    13:19
  3. 11.
    Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer
    27:28
  4. 12.
    Evolving Treatment Paradigm in Early-Stage EGFR-Mutant NSCLC: A Primer for Medical Oncologists
    16:21
  5. 13.
    Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists
    18:48
  6. 14.
    Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists
    26:24
  7. 15.
    Could PSMA Be the ‘Bulls-Eye’ Target in mCRPC?
    18:59
  8. 16.
    Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy
    25:58
  9. 17.
    Opportunistic Invasive Fungal Infections: Proactive Diagnosis of Patients at Risk
    23:13
  10. 18.
    Metastatic Urothelial Carcinoma: Maintaining Stable Disease
    15:33
  11. 19.
    "Complementing Evidence With Expert Experience: Challenging Cases in Paroxysmal Nocturnal Haemoglobinuria "
    43:06
  12. 20.
    Evolving the Treatment Paradigm in Metastatic HER2-Positive Breast Cancer: The Ongoing Story of Emerging Treatments
    15:09
  13. 21.
    When Physics Fuses With Medicine: A New Therapeutic Modality for mCRPC
    20:09
  14. 22.
    GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!
    19:14
  15. 23.
    Beyond HPIs for Advanced Basal Cell Carcinoma: Exploring the Clinical Implications of New Evidence
    19:46
  16. 24.
    Cardiovascular Risk and Prostate Cancer: Clinical Perspectives on ADT
    22:25
  17. 25.
    Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management
    16:01
  18. 26.
    A Look at Emerging SMA Outcomes: Highlights of WMS 2020
    9:12
  19. 27.
    Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies
    25:12
  20. 28.
    Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data
    18:49
  21. 29.
    Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?
    1:29:50
  22. 30.
    Practical Approaches to Optimise Management of Advanced Renal Cell Carcinoma
    21:08
  23. 31.
    Novel Therapies for Patients With DLBCL: What Does the Future Hold?
    1:04:21
  24. 32.
    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors
    12:32
  25. 33.
    A Patient-Centred Approach to Managing Prostate Cancer
    17:28
  26. 34.
    Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs
    15:42
  27. 35.
    Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease
    21:28
  28. 36.
    Hidden in Plain Sight: Uncovering Truncal Acne
    13:03
  29. 37.
    Extending Your Interdisciplinary Understanding of IL-6R Inhibitors in Rheumatoid Arthritis
    1:15:18
  30. 38.
    New Targets, New Hope in SMA: A 2020 Congress Coverage
    27:48
  31. 39.
    "Optimising the Use of JAK Inhibitors in RA: Translating the Latest Evidence Into Today’s Clinical Practice"
    23:26
  32. 40.
    Talking Meningococcal B Vaccines: Who Needs Protecting Now?
    20:01
  33. 41.
    Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer
    1:19:30
  34. 42.
    Treatment Update in CML: What’s New, and What Does it Mean for Patients?
    20:48
  35. 43.
    "Case Studies in Locally Advanced and Metastatic CSCC: Integrating Immunotherapy Into Current Treatment Paradigms"
    20:12
  36. 44.
    Hiding in Plain Sight: Identifying Patients at Risk for NASH
    24:34
  37. 45.
    Practical Lessons From Real-World Evidence on CDK 4/6 Inhibitors in Metastatic Breast Cancer
    22:01
  38. 46.
    Changing Strategies for Changing Times: Optimising Use of Targeted Alpha Therapies for Advanced Prostate Cancer
    23:32
  39. 47.
    Raising the Caliber of Non-Metastatic CRPC Care: Introducing Quality of Life Into the Equation
    37:42
  40. 48.
    Evolving the Treatment Paradigm in HER2-Positive Breast Cancer: Are New Options on the Horizon?
    15:22
  41. 49.
    Sequencing Therapy in mRCC: How Does an Evolving Treatment Pathway Change Decisions?
    16:06
  42. 50.
    Evolution of Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Approaches to Management
    30:25

Listen to PeerVoice Oncology & Haematology Audio now.

Listen to PeerVoice Oncology & Haematology Audio in full in the Spotify app